CymaBay Therapeutics, Inc.
CBAY · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $207 | $274 | $35 | $59 |
| Short-Term Investments | $188 | $165 | $178 | $177 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $10 | $9 | $10 | $6 |
| Total Curr. Assets | $404 | $448 | $224 | $243 |
| Property Plant & Equip (Net) | $6 | $1 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $22 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $3 | $3 | $2 | $2 |
| Total NC Assets | $31 | $3 | $3 | $3 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $435 | $451 | $227 | $245 |
| Liabilities | – | – | – | – |
| Payables | $4 | $3 | $5 | $2 |
| Short-Term Debt | $10 | $0 | $0 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $2 | $2 | $2 | $34 |
| Other Curr. Liab. | $21 | $15 | $11 | $11 |
| Total Curr. Liab. | $37 | $20 | $18 | $47 |
| LT Debt | $104 | $104 | $99 | $95 |
| Deferred Rev, NC | $1 | $1 | $1 | $0 |
| Deferred Tax Liab, NC | $0 | -$104 | -$99 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $106 | $105 | $100 | $95 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $142 | $125 | $118 | $141 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$978 | -$936 | -$902 | -$902 |
| AOCI | $0 | -$0 | -$0 | -$0 |
| Other Equity | $1,270 | $1,263 | $1,011 | $1,006 |
| Total Equity | $292 | $326 | $108 | $104 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $435 | $451 | $227 | $245 |
| Net Debt | -$92 | -$169 | $64 | $36 |